← Back to Search

Antiplatelet Agent

Clopidogrel vs. Aspirin for Staph Bloodstream Infection (Clopido-SNAP Trial)

Phase 4
Waitlist Available
Led By Todd C Lee, MD MPH FIDSA
Research Sponsored by Todd C. Lee MD MPH FIDSA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)
Be older than 18 years old
Must not have
Concomitant receipt of oral Xa inhibitor
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90 post enrollment in the s. aureus network adaptive platform trial (nct05137119)
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

This trial aims to see if switching from aspirin to clopidogrel can improve outcomes in patients with S. aureus bacteremia. Clopidogrel may have better effects against S. aure

Who is the study for?
This trial is for patients with a Staphylococcus aureus blood infection who are already using aspirin to prevent heart problems. It's part of a larger study and may lead to another trial if results are positive.
What is being tested?
The study compares the effects of continuing aspirin versus switching to clopidogrel, which might help fight the bacterial infection, in improving patient outcomes.
What are the potential side effects?
Possible side effects include bleeding risks, gastrointestinal issues like stomach pain or ulcers, allergic reactions, and sometimes severe skin conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am taking aspirin to prevent further heart or blood vessel disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking an oral Xa inhibitor medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90 post enrollment in the s. aureus network adaptive platform trial (nct05137119)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 90 post enrollment in the s. aureus network adaptive platform trial (nct05137119) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Desirability of Outcome Ranking (DOOR)
Secondary study objectives
All cause mortality
Clinical Failure
Clinically relevant acute myocardial infarction
+6 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Change to clopidogrelExperimental Treatment1 Intervention
Patients will have their aspirin discontinued and start clopidogrel.
Group II: Continue aspirinActive Control1 Intervention
Patients will continue their existing aspirin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clopidogrel
2010
Completed Phase 4
~9160

Find a Location

Who is running the clinical trial?

Todd C. Lee MD MPH FIDSALead Sponsor
2 Previous Clinical Trials
360 Total Patients Enrolled
2 Trials studying Staphylococcus Aureus Endocarditis
360 Patients Enrolled for Staphylococcus Aureus Endocarditis
Todd C Lee, MD MPH FIDSAPrincipal InvestigatorResearch Institute of the McGill University Health Centre
4 Previous Clinical Trials
730 Total Patients Enrolled
2 Trials studying Staphylococcus Aureus Endocarditis
360 Patients Enrolled for Staphylococcus Aureus Endocarditis
Emily G McDonald, MD MScPrincipal InvestigatorResearch Institute of the McGill University Health Centre
4 Previous Clinical Trials
673 Total Patients Enrolled
1 Trials studying Staphylococcus Aureus Endocarditis
60 Patients Enrolled for Staphylococcus Aureus Endocarditis
~200 spots leftby Jan 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top